Day 1 – May 17th, 2016
Short course
08.30-09.00: Registration + coffee
09h00-17h30: Bayesian methods for longitudinal data
Instructor: Mike Daniels, University of Texas, US
Day 2 – May 18th, 2016
08h30-9h15: Registration + coffee
09h15-9h30: Welcome + practical details
Invited talk
09h30-10h30: Gregory Campbell, Formerly FDA, US
Bayesian statistics in medical device clinical trials: Great progress and some challenges
10h30-11h00: Coffee break + posters
Contributed talks
11h00-11h20: Leacky Muchene, Hasselt University, Belgium
11h20-11h40: Marco Munda,Arlenda SA, Belgium
11h40-12h00: Adrian Quintero, KU Leuven, Belgium
Marginal deviance information criterion for latent variable models
12h00-13h30: Lunch
Invited talk
13h30-14h30: Tarek Haddad, MedTronics, US
Incorporation of stochastic engineering models as prior information in Bayesian medical device trials and post-market surveillance
Contributed talks
14h30-14h50: Kathrin Hatz, Bayer Technology Services GmbH, Germany
Using Bayesian-PBPK modelling for assessment of inter-individual variability and subgroup stratification
14h50-15h10: Leonhard Held, University of Zurich, Switzerland
What’s the evidence? On P-values and Bayes factors
15h10-15h40: Coffee break + posters
15h40-16h00: Joris Menten, Janssen Pharmaceutics, Belgium
A general Bayesian framework for the meta-analysis of diagnostic accuracy studies
16h00-16h20: David Mawdsley, University of Bristol, UK
16h20-16h40: Victoria N Nyaga, Hasselt University, Belgium
16h40-17h00: Igor André Milhorança, KU Leuven, Belgium
Models for multivariate multilevel Likert scales
18h00-20h00: Beer sightseeing tour Leuven
Day 3 – May 19th , 2016
Invited talk
09h00-10h00: Martin Posch, U Vienna, Austria
An extrapolation framework to specify requirements for drug development in children
10h00-10h30: Coffee break + posters
Contributed talks
10h30-10h50: Clara Domínguez-Islas, Cambridge University, UK
Robust bivariate meta-analytic-predictive priors for including historical information on control rates and treatment effects in paediatric clinical trials
10h50-11h10: Isaac Gravestock, University of Zurich, Switzerland
Practical informative priors based on historical data with Empirical Bayes
11h10-11h30: David Dejardin,F. Hoffmann-La Roche AG, Switzerland
Decision making in basket trials: A hierarchical weights approach
11h30-11h50: Timothy Mutsvari, Arlenda SA, Belgium and Rosalind Walley, UCB Celltech, UK
Addressing potential prior-data conflict when using informative priors in proof-of-concept studies
12h00-13h30: Lunch
Invited talk
13h30-14h30: Invited speaker: Alberto Sorrentino, U Genova, Italy
Sequential Monte Carlo algorithms for Bayesian imaging in neuroscience
14h30-15h00: Coffee break + posters
Invited talk
15h00-16h00: Kyle Wathen, Johnson and Johnson, US
A Bayesian approach to risk based monitoring
Contributed talks
16h00-16h20: Carl Di Casoli, Bayer, Germany
The case for Bayesian methods in benefit-risk assessment: Overview and future directions
16h20-16h40: Baldur Magnusson, Novartis Pharma AG, Switzerland
Dose escalation design in malaria
16h40-17h00: Anne Benoit, GlaxoSmithKline Biologicals, Belgium
Taking into account strains heterogeneity in the estimation of vaccine efficacy against seasonal influenza
19h30-23h00: Conference dinner in De Clyne Tafel
Day 4 – May 20th , 2016
Invited talk
09h00-10h00: Robert Noble, GSK, UK
Properties of a Bayesian sequential design to investigate delayed graft function after renal transplantation
10h00-10h30: Coffee break
Contributed talks
10h30-10h50: Pierre Lebrun, Arlenda SA, Belgium
Manufacturing process simulation: from bioreactor to shelf-life using Bayesian predictions
10h50-11h10: Martin Otava, Janssen Pharmaceutics, Belgium
11h10-11h30: Luwis Diya, Janssen Pharmaceutics, Belgium
Modelling stability of dissolution for a drug product
11h30-11h50: Laurent Natalis, Arlenda SA, Belgium
A Bayesian framework to compute internal release limits (IRL) for products with linear and non-linear degradations
11h50-12h10: Farewell
12h10-14h00: Lunch
Posters:
- Bayesian Enrollment Predictions in Clinical Trials Leveraging Regional Data, Aijun Gao, Ventiv Health Clinical and Fanni Natanegara, Eli Lilly and Company
- Bayesian Designs for Phase I Clinical Trial, Yuh-Ing Chen, Institute of Statistics, National Central University
- Assessing Drug Safety with Bayesian Hierarchical Modeling Using PROC MCMC and JMP®, Valérie Nedbal, SAS Institute GmbH.
- Bayesian Solution for the Unique Challenges of Continuous Manufacturing of Pharmaceutical Products, Tara Scherder, Arlenda, Inc, Katherine Giacoletti, Arlenda, Inc, Steven Novick, Medimmune, formerly of Arlenda, Inc
- Characterization of a system used to expose organ-like tissues to aerosols: a Bayesian analysis of a split-split-plot design, S. Kleinhans*, G. Vuillaume*, S. Steiner, S. Majeed, S. Frentzel, F. Martin, J. Hoeng, Philip Morris, Products S.A.
- Model Based Classification of Monotone Gene Profiles using Bayesian Variable Selection, Rudradev Sengupta Ziv Shkedy Martin Otava, Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat)
- Methods Comparison for Oncology Phase I Dose finding Studies, Rong Liu, Bayer Healthcare, Wanying Zhao, George Washington University
- Using Hierarchical Bayesian model for detection of Gene Differential Splicing: The Genome-wide Differential Splicing (GDS) model, Marijke Van Moerbeke1, Adetayo Kasim2 and Ziv Shkedy1 1 Institute for Biostatistics and Statistical Bioinformatics, Hasselt 2 Department of Statistics, Durham University, United Kingdom
- Transferring cut-off values between assays for Alzheimer’s disease CSF-biomarkers., L. García Barrado1*, E. Coart2, and T. Burzykowski1,2 1Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-Biostat) 2International Drug Development Institute (IDDI)
- Fast MCMC on Graphics Processing Units, David C. Norris
